

# Ophthalmology<sup>®</sup>

## ROUNDS

AS PRESENTED IN THE  
ROUNDS OF THE DEPARTMENT  
OF OPHTHALMOLOGY  
AND VISION SCIENCES,  
FACULTY OF MEDICINE,  
UNIVERSITY OF TORONTO



Ophthalmology & Vision Sciences  
UNIVERSITY OF TORONTO

## Top 5 Diagnoses Not to Miss in Children

BY STEPHANIE N. KLETKE, MD, AND MICHAEL J. WAN, MD, FRCSC

This issue of *Ophthalmology Rounds* focuses on 5 of the most important eye conditions in children that should not be missed. Any clinician who sees children should be familiar with these potentially vision and life-threatening diseases. This article summarizes the clinical presentation, differential diagnosis, assessment, and management of the key pediatric causes of leukocoria, epiphora, ptosis, proptosis, and neurological disease.

### 1. White Pupillary Reflex

Leukocoria, also known as a “white pupil,” results from the reflection of light off a media opacity or retinal lesion during direct fundus illumination. It may first be observed in flash photography or detected by the child’s family or pediatrician. Any child with an abnormal red reflex should be referred urgently to an ophthalmologist, as it is imperative not to miss the life-threatening diagnosis of retinoblastoma. While the differential diagnosis of leukocoria includes cataract, familial exudative vitreoretinopathy, toxocariasis, retinopathy of prematurity, and coloboma, key considerations include persistent fetal vasculature (PFV) and Coats disease.

Retinoblastoma is the most common primary intraocular malignancy of childhood, with a worldwide incidence of 1 in 15 000–20 000 live births.<sup>1</sup> About 23 children are diagnosed each year in Canada.<sup>2</sup> The tumour arises in the developing retina following inactivation of both copies of the *RB1* gene, a tumour-suppressor located at chromosome 13q14.2.<sup>3,4</sup> This leads to loss of functional retinoblastoma protein and uncontrolled cell division. The origin of retinoblastoma may be a cone precursor cell, which remains within the inner nuclear layer.<sup>5,6</sup>

Retinoblastoma presents as a small, round, grey intraretinal tumour that initially undergoes symmetrical growth.<sup>7</sup> Over time, the growth becomes lobulated due to clonal growth differences. As the disease progresses, the tumour may breach the inner limiting membrane and lead to vitreous seeding, or extend into the subretinal space causing subretinal seeding and exudative retinal detachment (Figure 1A). Signs of advanced disease include phthisis bulbi, anterior chamber invasion, elevated intraocular pressure (IOP) with neovascularization, hyphema, or aseptic orbital cellulitis.<sup>8</sup> The tumour can spread via the optic nerve or subarachnoid space to the central nervous system, invade adjacent orbital structures, and disseminate hematogenously via the choroid, most commonly to bone marrow.

When retinoblastoma is suspected, a complete clinical examination under anesthesia (EUA) including IOP measurement, anterior segment evaluation and indirect ophthalmoscopy with scleral indentation should be performed.<sup>2</sup> B-scan ultrasonography shows typical calcification. Useful imaging modalities include RetCam™, fluorescein angiography and ultrasound biomicroscopy for assessing anterior involvement.<sup>9,10</sup> Optical coherence tomography (OCT) aids in detecting small tumours and evaluating foveal architecture, which influences management decisions.<sup>11</sup> Magnetic resonance imaging (MRI) of the brain and orbits assesses for extraocular or optic nerve involvement, as well as intracranial midline embryonic tumours. Computed tomography (CT) is no longer recommended given the increased risk of second primary neoplasms following radiation exposure in children with germline mutations. Molecular genetic testing dictates the frequency of EUAs to monitor for new ocular tumours and surveillance for second neoplasms.<sup>2</sup>

Staging of the disease extent at presentation helps to select appropriate therapy and predict outcomes. The Reese-Ellsworth classification was originally used to predict eye salvage following external-beam radiation therapy.<sup>12</sup> The International Intraocular Retinoblastoma Classification later staged eyes from Group A (very low risk) through E (very high risk) and predicted outcomes following systemic chemoreduction and focal therapies.<sup>7</sup> The 8<sup>th</sup> edition of the American Joint Committee on Cancer Tumor, Node, Metastasis and Heritable trait (TNMH) system was introduced recently to stage for overall prognosis.<sup>8</sup>

**Department of Ophthalmology and Vision Sciences**  
Sherif El-Defrawy, MD  
Professor and Chair  
Jeffrey J. Hurwitz, MD  
Editor, *Ophthalmology Rounds*  
Valerie Wallace, PhD  
Director of Research

**The Hospital for Sick Children**  
Agnes Wong, MD  
Ophthalmologist-in-Chief

**Mount Sinai Hospital**  
David B. Yan, MD  
Ophthalmologist-in-Chief

**Princess Margaret Hospital (Eye Tumour Clinic)**  
Hatem Krema, MD  
Director, Ocular Oncology Service

**St. Michael’s Hospital**  
David Wong, MD  
Ophthalmologist-in-Chief

**The John and Liz Tory Eye Centre Sunnybrook Health Sciences Centre**  
Peter J. Kertes, MD  
Ophthalmologist-in-Chief

**University Health Network Toronto Western Hospital Division**  
Robert G. Devenyi, MD  
Ophthalmologist-in-Chief

**Kensington Eye Institute**  
Sherif El-Defrawy, MD  
Ophthalmologist-in-Chief


**Department of Ophthalmology and Vision Sciences, Faculty of Medicine, University of Toronto,**  
60 Murray St.  
Suite 1-003  
Toronto, ON M5G 1X5

The editorial content of *Ophthalmology Rounds* is determined solely by the Department of Ophthalmology and Vision Sciences, Faculty of Medicine, University of Toronto

**NEW!  
READER FORUM**

Please visit [www.ophtalmologyrounds.ca](http://www.ophtalmologyrounds.ca) and follow the Comments link to submit a comment on a recent issue and to read what your colleagues are contributing to the dialogue.

**Figure 1. 1A:** A funnel-shaped exudative retinal detachment overlying tumour with both vitreous and subretinal seeds in a child with retinoblastoma. **1B:** Fundus photograph of a child with Coats disease. Note the total exudative retinal detachment and prominent retinal telangiectasia.



Retinoblastoma can be fatal if left untreated. The goals of care are, first, to save the child's life, followed by eye and vision salvage. Treatment is dictated by the staging, laterality of disease and genetic status, and should involve a multidisciplinary team including pediatric oncology. Focal therapies (laser photocoagulation for posterior or cryotherapy for peripheral tumours) are used for treating small tumours that spare the optic nerve and fovea, while larger or vision-threatening tumours may require systemic chemoreduction with focal consolidation.<sup>13</sup> Enucleation serves as a definitive treatment for advanced unilateral tumours.<sup>2</sup> Intravitreal melphalan has shown success in control of vitreous seeding.<sup>14</sup> Finally, intra-arterial chemotherapy has emerged as a treatment for select patients.<sup>15</sup>

### Differential diagnosis


PFV is an isolated, sporadic congenital malformation caused by arrest of the normal regression of the fetal vasculature. It is typically unilateral and can present with a spectrum of anterior and posterior segment manifestations, including microphthalmos and elongated ciliary processes. The most common sign is leukocoria, which is secondary to dense retrolental plaque and cataract formation.<sup>16</sup>

Coats disease is the most clinically challenging disease to differentiate from retinoblastoma.<sup>17,18</sup> It is usually unilateral and presents in males at a median age of 5 years.<sup>19</sup> Coats disease is an idiopathic, nonhereditary retinal telangiectasia with associated intraretinal and subretinal lipid exudation. Advanced cases present with exudative retinal detachment and mimic retinoblastoma (Figure 1B). Fundus examination in both upright and supine positions, to visualize the inferior retina, is important to distinguish these conditions.<sup>18</sup> FA and ultrasonography may be useful adjuncts. While laser and intravitreal anti-vascular endothelial growth factor therapies have been reported, enucleation is the safest management option in advanced cases with diagnostic uncertainty.<sup>18</sup>

## 2. The Tearing Eye

Nasolacrimal duct obstruction, typically the result of a thin membrane present at the distal valve of Hasner, is the most common cause of epiphora and periocular crusting in infants (Figure 2A). Since 90% resolve spontaneously within the first year of life, conservative management with lacrimal massage is preferred.<sup>20</sup> Persistent obstruction after 1 year of age warrants probing and, when necessary, balloon catheter dilation, silicone tube intubation, or dacryocystorhinostomy.<sup>20</sup> While tearing in children can also be a sign of conjunctivitis, keratitis, or

**Figure 2. 2A:** This child presented with a left nasolacrimal duct obstruction. Note the epiphora and periocular crusting. **2B:** Infant with congenital glaucoma. Note the buphthalmos and corneal opacification.



lid abnormalities such as epiblepharon, the most important etiology that must not be missed is primary congenital glaucoma (PCG).

The Childhood Glaucoma Research Network classifies childhood glaucoma as PCG, juvenile open angle glaucoma, glaucoma associated with acquired conditions, nonacquired systemic syndromes (eg, Marfan, Sturge-Weber, or Lowe), nonacquired ocular anomalies (eg, Axenfeld Rieger syndrome, aniridia, or Peters anomaly), and glaucoma following cataract surgery.<sup>21</sup> PCG is an isolated goniodysgenesis leading to increased resistance to aqueous outflow. It is the most common type of childhood glaucoma and presents with the classic triad of epiphora, photophobia, and blepharospasm. PCG can be further classified as neonatal ( $\leq 1$  month), infantile ( $>1$ -24 months), and late-onset ( $>2$  years).<sup>21</sup>

Examination of the tearing infant should include assessment of visual acuity (VA), pupils, and IOP, preferably before general anesthesia induction. IOP can also be measured in clinic using the Icare<sup>®</sup> tonometer.<sup>22</sup> In infants, elevated IOP ( $>12$  mmHg in newborns) leads to distention of the cornea, paired curvilinear breaks in Descemet membrane known as Haab striae, corneal edema, and buphthalmos (Figure 2B). Horizontal corneal diameter (HCD) and axial length (AL) are greater than age-matched controls, with HCD more sensitive in identifying congenital glaucoma.<sup>23</sup> HCD  $>11$  mm in a newborn and  $>13$  mm at any age is suggestive of PCG. Serial AL measurements are useful to monitor the course of PCG, as AL may decrease or parallel normal growth with improvement in IOP.<sup>24</sup> Pachymetry, anterior segment examination, and gonioscopy should also be performed. Circumferential cupping with a cup-to-disc ratio  $>0.3$  or asymmetry  $>0.2$  is suggestive of PCG. Cycloplegic refraction shows a myopic shift with progressive axial elongation.

The treatment of PCG is primarily surgical, with IOP-lowering medications used as adjunctive therapy. Angle surgery such as goniotomy (ab interno), which requires a relatively clear cornea, and trabeculotomy (ab externo) allow aqueous access to the Schlemm canal.<sup>25</sup> Other surgical options include trabeculectomy with adjunctive mitomycin C, combined trabeculotomy-trabeculectomy, glaucoma drainage devices, and cyclophotocoagulation. IOP reduction can lead to improved corneal edema and stabilization or reversal of optic nerve cupping. Concurrent correction of refractive errors and amblyopia therapy is essential. Long-term monitoring of children with PCG is critical to assess for progression.

## 3. More Than Just a Droopy Lid

Roughly 75% of childhood ptosis is simple congenital ptosis, which may require surgical correction but is not associated with any serious underlying disease;<sup>26</sup> however, rare but dangerous cases of ptosis should not be missed. Three

potentially life-threatening conditions in children can present with ptosis: Horner syndrome, oculomotor palsy, and myasthenia gravis (MG).

### Horner syndrome

Horner syndrome is due to a lesion of the sympathetic nerve pathway. It is known for the classic “osis” triad of ipsilateral ptosis, miosis, and anhidrosis. Children with Horner syndrome generally have 1-2 mm of upper eyelid ptosis (due to denervation of the Muller muscle) associated with a characteristic “reverse ptosis” in which the lower eyelid is higher due to denervation of the lower lid retractors. Parents often report that the eye looks “smaller” as opposed to noting the eyelid changes (Figure 3A). The anisocoria is greater in dim illumination and associated with dilation lag of the miotic pupil. Heterochromia, another important finding, indicates that the Horner syndrome is congenital or early-onset. In order to confirm the diagnosis, instill 4% cocaine drops into each eye; anisocoria  $\geq 0.8$  mm after 1 hour accurately confirms the diagnosis. There is no need to measure the change in anisocoria, just the post-cocaine difference.<sup>27</sup> A more easily accessible alternative to cocaine is 0.5%–1% topical apraclonidine, which will reverse the anisocoria in Horner syndrome;<sup>28–30</sup> however, apraclonidine can cause extreme drowsiness in infants and is therefore contraindicated in infants  $< 6$  months and should be used cautiously in children  $< 2$  years.<sup>31</sup>


If the cause of Horner syndrome is known (eg. perinatal trauma, neck/cardiothoracic surgery) or there is heterochromia in an older child, no further work-up is required. If there is no known cause, a thorough assessment for neuroblastoma is mandatory as there is a significant risk of a mass lesion along the sympathetic pathway.<sup>32</sup> Urine catecholamines, abdominal ultrasound, and chest x-ray are useful and easily accessible tests, but the definitive test to rule out neuroblastoma is a head, neck, and chest MRI with contrast.<sup>32</sup>

### Oculomotor (cranial nerve III) palsy

The oculomotor nerve innervates several important muscles, including 4 of the 6 extraocular muscles (medial/superior/inferior recti muscles and inferior oblique), the levator palpebrae superioris, and the sphincter pupillae muscle via the ciliary ganglion. As such, a complete oculomotor palsy causes severe ptosis, a blown pupil, and large-angle exotropia with moderate hypotropia. However, injury to the oculomotor nerve may not affect all muscles and the weakness may be partial. Therefore, in any case of ptosis, it is crucial to be vigilant for any associated signs of cranial nerve III injury (Figure 3B).

The most common cause of an isolated oculomotor palsy in children is congenital, followed by trauma, which collectively make up about two-thirds of all cases.<sup>33</sup> The remaining cases are due to infection/inflammation, tumour, aneurysm, and ophthalmoplegic migraine. Unless the cause is known, all cases require an urgent MRI / MR angiography and neurological assessment. Following an acute injury, the oculomotor nerve may recover and so surgical repair of ptosis and strabismus should be delayed  $\geq 6$  months. However, complete ptosis combined with large-angle strabismus is highly amblyogenic, so young children with oculomotor palsy need to be monitored closely for amblyopia.<sup>34</sup>

**Figure 3.** Potentially life-threatening conditions that can present with ptosis. **3A:** Right Horner syndrome with mild ptosis, reverse ptosis, and miosis. **3B:** Right oculomotor palsy with moderate ptosis, large-angle exotropia, hypotropia, and a dilated pupil. **3C:** Myasthenia gravis with bilateral, asymmetric ptosis.



### Myasthenia gravis (MG)

While rare in children, MG does occur and can be a diagnostic challenge. MG is a disorder of the neuromuscular junction that causes weakness, often presenting with ptosis and/or strabismus. The ptosis is highly variable (Figure 3C) and can be mistaken for more common conditions such as simple congenital ptosis.<sup>35</sup> The eye movements also do not follow a consistent pattern and can imitate any pattern of ocular misalignment. Given the variability in clinical presentation, the key clinical features of MG are fatigability and fluctuation. The ptosis and strabismus change throughout the day and will characteristically be worse with use/exercise and better with rest; however, the finding of “worse at the end of the day” is not pathognomonic of MG. MG does not affect the pupil and so any pupillary findings such as anisocoria strongly indicate a different underlying etiology.

When MG is suspected, acetylcholinesterase inhibitor antibodies should be ordered and the child should be referred to neurology for further testing.<sup>36,37</sup> It is crucial not to miss ocular MG, as most children who present with ocular findings will eventually go on to develop generalized weakness and, in severe cases, are at risk of respiratory failure and death.<sup>38</sup>

### 4. When the Problem Lies Behind the Eye

The onset of proptosis in a child warrants urgent evaluation to rule out an infectious, inflammatory, vascular, or neoplastic orbital process. Ask about recent trauma, upper respiratory or sinus disease, and immunocompromise. The examination should identify orbital signs such as ptosis, eyelid edema, conjunctival chemosis, restricted extraocular movements, and increased resistance to retropulsion, as well as signs of compressive optic neuropathy.

### Orbital cellulitis

Orbital cellulitis is an infection involving the tissues posterior to the orbital septum. The most common etiology is ethmoidal sinusitis,<sup>39</sup> but penetrating orbital trauma should be excluded. Children present with eyelid erythema and edema, proptosis, external ophthalmoplegia, chemosis, fever, lethargy, and pain. Prompt diagnosis, hospitalization, and initiation of broad-spectrum intravenous (IV) antibiotics and daily follow-up are crucial.



CT orbit can assess the extent of sinusitis and the presence of subperiosteal abscess (SPA).<sup>39</sup> This occurs secondary to accumulation of purulent material between the orbital bone and periorbital. Culture-positive cases from SPAs demonstrate single microbial aerobic infections (*Streptococcus* and *Staphylococcus*) in children <9 years.<sup>40</sup> Children aged 9–14 years show a transition toward more complex infections, while those >15 years show polymicrobial aerobic and anaerobic (*Bacteroides*) infections, with an average of 5 different species isolated per abscess.<sup>40</sup>

The Chandler classification of orbital cellulitis includes Group I (inflammatory eyelid edema), Group II (orbital cellulitis), Group III (subperiosteal abscess), Group IV (orbital abscess), and Group V (posterior extension leading to cavernous sinus thrombosis, frank meningitis, or brain abscess).<sup>41</sup>

The mainstay of treatment is broad-spectrum IV antibiotics and nasal decongestants. The antibiotics should be tapered to oral following clinical improvement. While conservative management is appropriate for small SPAs, surgical drainage should be considered if there is inadequate response to medical management after 24–48 hours, evidence of optic nerve compromise, or a worsening clinical course.<sup>42</sup> Patients requiring surgery tend to be older (>6 years), have larger abscesses (>10 mm), and require longer admissions.<sup>42</sup> The size of the SPA on CT orbit is significantly correlated with management outcome; an SPA volume >3.8 mL is associated with a 71% probability of requiring surgery.<sup>39</sup> Finally, oral prednisone 1 mg/kg daily for 7 days has been shown to be beneficial and a standardized starting point of C-reactive protein <4 mg/dL has been proposed.<sup>43</sup>

### Rhabdomyosarcoma (RMS)

Acute onset of unilateral painless proptosis, ptosis, and lid edema or ecchymoses in a child should raise the suspicion of RMS, the most common pediatric primary orbital malignancy. RMS is a neoplasm of primitive mesenchyme expressing skeletal muscle differentiation. Primary orbital RMS originates most commonly in the orbit, followed by the conjunctiva, uveal tract and eyelid, and presents at a mean age of 10 years.<sup>44</sup> The most common orbital site is the superonasal quadrant.<sup>45</sup> On CT, the tumour has an irregular shape with homogenous soft tissue density, moderately well-defined margins and shows contrast enhancement.<sup>45</sup> On MRI the tumour is isointense on T1 and hyperintense on T2 relative to muscle (Figures 4A, 4B).<sup>45</sup>

Histopathology is required to confirm the diagnosis. The International Classification of Rhabdomyosarcoma includes 6 histopathological subtypes: embryonal – botryoid, embryonal – spindle cell, embryonal – not otherwise specified, alveolar – solid variant, anaplasia – diffuse, and undifferentiated sarcoma.<sup>46</sup> The Surgical-Pathologic Grouping System of the Intergroup Rhabdomyosarcoma Study (IRS) includes groups I through IV, based on the extent of the tumour and the presence of complete resection, microscopic or gross residual disease following surgery.<sup>47</sup> This is an important predictor of treatment

outcome. RMS can also be staged by the IRS TNM system, which dictates management. Given the tendency for local invasion and recurrence, as well as haematogenous and lymphatic metastases, management includes combinations of surgical resection, systemic chemotherapy, and radiotherapy.<sup>44,48</sup>

### 5. The Brain


The onset of serious neurological disease is often marked by characteristic ophthalmic signs and symptoms. The key to not missing a neurological etiology is a consistent, systematic approach to the history and examination that incorporates screening for important “red flags” of optic nerve and intracranial disease.

On history, important symptoms of neurological disease include headaches, double vision, eye pain (particularly with eye movement), and the loss of colour vision or VA. In any child with headaches, ask about associated symptoms of high intracranial pressure, including nausea, vomiting, pulsatile tinnitus, transient visual obscurations, and diplopia.<sup>49</sup> With diplopia, it is crucial to differentiate between monocular and binocular versions; binocular diplopia is a red flag for neurological disease and disappears when one eye is closed. The simultaneous loss of VA and colour vision is typical of optic nerve disease, and pain with eye movement is highly suggestive of optic neuritis.<sup>50</sup>

A thorough examination is indispensable in children, who may be unable to accurately verbalize symptoms of neurological disease. At minimum, the examination should include testing of VA, pupils, visual fields, eye movements, and a dilated fundus examination with particular attention to the optic nerve.

VA testing should be age appropriate to avoid errors due to poor understanding or cooperation.<sup>51,52</sup> If VA is asymmetric, check for a relative afferent pupillary defect, which is a sensitive sign of unilateral optic nerve disease. Assess the pupils for anisocoria, which is an important sign of Horner syndrome and oculomotor palsy. If the child is cooperative, check visual fields for a homonymous or bitemporal hemianopia, which are both red flags for neurological disease and often go unnoticed by children. When checking eye movements, assess all cardinal positions of gaze to look for evidence of a cranial nerve III, IV, or VI palsy. A cranial nerve IV palsy usually presents as a head tilt away from the side of the palsy and/or vertical binocular diplopia. In particular, look for a hypertropia that increases with contralateral gaze and ipsilateral head tilt (ie, the 3-step test).<sup>53</sup> Cranial nerve VI palsies usually present with an

**Figure 4. 4A:** This child presented with rapid-onset proptosis without signs of infection or inflammation. **4B:** Magnetic-resonance imaging showed a superonasal enhancing orbital mass, which was diagnosed as rhabdomyosarcoma on biopsy.



abduction deficit, but may also manifest as an esotropia that is greater in side gaze (lateral incomitance) or at distance (divergence insufficiency).<sup>54,55</sup>

Finally, a dilated fundus examination is crucial, as both optic nerve edema and atrophy indicate neurological disease. Bilateral optic nerve edema without vision loss is highly suggestive of papilledema, especially when accompanied by symptoms of high intracranial pressure.<sup>49</sup> There is significant clinical overlap between mild papilledema and pseudopapilledema (eg, optic disc drusen), so ocular imaging such as B-scan ultrasound and OCT can be very helpful in differentiating true papilledema from pseudopapilledema. Bilateral optic disc edema can also occur secondary to systemic conditions such as malignant hypertension, so a general review of systems is important.<sup>56</sup> Optic atrophy is a key finding in many intracranial and optic nerve diseases. While optic atrophy is easily detected when severe, mild optic atrophy can be particularly subtle. In these cases, OCT can be very helpful, as studies of healthy children have found that an average retinal nerve fiber layer thickness <84 µm is usually abnormal (ie, below the 99<sup>th</sup> percentile).<sup>57,58</sup>

If an acute neurological disease is suspected, an urgent MRI of the brain and orbit and a neurological assessment is usually warranted. With papilledema, an MRV should be added to look for sinus venous thrombosis. In some cases where the issue is likely longstanding, such as a congenital cranial nerve IV palsy, further work-up may be unnecessary, and the patient can simply be followed or referred to neuro-ophthalmology for assessment.

## Conclusion

A child presenting with leukocoria, epiphora, ptosis, proptosis or neurological red flags should prompt the clinician to assess for vision and life-threatening conditions. It is important to have a structured approach to the evaluation of children of different ages and to be aware of investigations and initial management options for these key diagnoses.

**Dr. Kletke** is a Senior Resident, Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario. **Dr. Wan** is an Assistant Professor, Department of Ophthalmology and Vision Sciences, University of Toronto, and a Paediatric Ophthalmologist, SickKids Hospital, Toronto, Ontario.

## References

- Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma. *Lancet*. 2012;379(9824):1436-1446.
- Canadian Retinoblastoma Society. National Retinoblastoma Strategy Canadian Guidelines for Care: Strategie thérapeutique du retinoblastome guide clinique canadien. *Can J Ophthalmol*. 2009;44(Suppl 2):S9-88.
- Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci U S A*. 1971;68(4):820-823.
- Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature*. 1986;323(6089):643-646.
- Xu XL, Singh HP, Wang L, et al. Rb suppresses human cone-precursor-derived retinoblastoma tumours. *Nature*. 2014;514(7522):385-388.
- Soliman SE, Racher H, Zhang C, MacDonald H, Gallie BL. Genetics and Molecular Diagnostics in Retinoblastoma—An Update. *Asia Pac J Ophthalmol (Phila)*. 2017;6(2):197-207.
- Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. *Ophthalmol Clin North Am*. 2005;18(1):41-53, viii.
- Amin MB, Edge S, Greene F, et al (eds). *AJCC Cancer Staging Manual*. 8th ed. New York, NY: Springer International Publishing; 2017.
- Vasquez LM, Giuliani GP, Halliday W, Pavlin CJ, Gallie BL, Heon E. Ultrasound biomicroscopy in the management of retinoblastoma. *Eye (Lond)*. 2011;25(2):141-147.
- Valenzuela A, Chan HSL, Heon E, Gallie BL. A language for retinoblastoma: guidelines and standard operating procedures. In: Reynolds J, ed. *Pediatric Retina*. New York, NY: Marcel Dekker Inc; 2010:205-234.
- Soliman SE, VandenHoven C, MacKeen LD, Heon E, Gallie BL. Optical coherence tomography-guided decisions in retinoblastoma management. *Ophthalmology*. 2017;124(6):859-872.
- Ellsworth RM. Retinoblastoma. *Mod Probl Ophthalmol*. 1977;18:94-100.
- Abramson DH, Shields CL, Munier FL, Chantada GL. Treatment of retinoblastoma in 2015: agreement and disagreement. *JAMA Ophthalmol*. 2015;133(11):1341-1347.
- Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. *Br J Ophthalmol*. 2012;96(8):1078-1083.
- Yousef YA, Soliman SE, Astudillo PP, et al. Intra-arterial chemotherapy for retinoblastoma: a systematic review. *JAMA Ophthalmol*. Mar 17 2016 [Epub ahead of print]
- Balmer A, Munier F. Differential diagnosis of leukocoria and strabismus, first presenting signs of retinoblastoma. *Clin Ophthalmol*. 2007;1(4):431-439.
- Huang S, Rutar T, Bloomer M, Crawford JB. Analysis of clinical misdiagnoses in children treated with enucleation. *Arch Ophthalmol*. 2010;128(8):1009-1013.
- Soliman SE, Wan MJ, Heon E, Hazrati LN, Gallie B. Retinoblastoma versus advanced Coats' disease: Is enucleation the answer? *Ophthalmic Genet*. 2017;38(3):291-293.
- Shields JA, Shields CL, Honavar SG, Demirci H. Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial Lecture. *Am J Ophthalmol*. 2001;131(5):561-571.
- Takahashi Y, Kakizaki H, Chan WO, Selva D. Management of congenital nasolacrimal duct obstruction. *Acta Ophthalmol*. 2010;88(5):506-513.
- Beck A, Chang CT, Freedman S. Definition, classification, differential diagnosis. In: Weinreb RN, Grajewski A, Papadopoulos M, Grigg J, Freedman S, eds. *Childhood Glaucoma*. Amsterdam (Netherlands): Kugler Publications; 2013.
- Grigorian F, Grigorian AP, Olitsky SE. The use of the iCare tonometer reduced the need for anesthesia to measure intraocular pressure in children. *J AAPOS*. 2012;16(6):508-510.
- Kiskis AA, Markowitz SN, Morin JD. Corneal diameter and axial length in congenital glaucoma. *Can J Ophthalmol*. 1985;20(3):93-97.
- Law SK, Bui D, Caprioli J. Serial axial length measurements in congenital glaucoma. *Am J Ophthalmol*. 2001;132(6):926-928.
- Chen TC, Chen PP, Francis BA, et al. Pediatric glaucoma surgery: a report by the American Academy Of Ophthalmology. *Ophthalmology*. 2014;121(11):2107-2115.

26. Griepentrog GJ, Diehl NN, Mohny BG. Incidence and demographics of childhood ptosis. *Ophthalmology*. 2011; 118(6):1180-1183.
27. Kardon RH, Denison CE, Brown CK, Thompson HS. Critical evaluation of the cocaine test in the diagnosis of Horner's syndrome. *Arch Ophthalmol*. 1990;108(3):384-387.
28. Morales J, Brown SM, Abdul-Rahim AS, Crosson CE. Ocular effects of apraclonidine in Horner syndrome. *Arch Ophthalmol*. 2000; 118(7):951-954.
29. Brown SM, Aouchiche R, Freedman KA. The utility of 0.5% apraclonidine in the diagnosis of horner syndrome. *Arch Ophthalmol*. 2003; 121(8):1201-1203.
30. Bacal DA, Levy SR. The use of apraclonidine in the diagnosis of horner syndrome in pediatric patients. *Arch Ophthalmol*. 2004; 122(2):276-279.
31. Watts P, Satterfield D, Lim MK. Adverse effects of apraclonidine used in the diagnosis of Horner syndrome in infants. *J AAPOS*. 2007; 11(3):282-283.
32. Mahoney NR, Liu GT, Menacker SJ, Wilson MC, Hogarty MD, Maris JM. Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions. *Am J Ophthalmol*. 2006;142(4):651-659.
33. Miller NR. Solitary oculomotor nerve palsy in childhood. *Am J Ophthalmol*. 1977;83(1):106-111.
34. Schumacher-Feero LA, Yoo KW, Solari FM, Biglan AW. Results following treatment of third cranial nerve palsy in children. *Trans Am Ophthalmol Soc*. 1998;96:455-472; discussion 472-454.
35. Alam MS, Devi Nivean P. Early onset bilateral juvenile myasthenia gravis masquerading as simple congenital ptosis. *GMS Ophthalmol Cases*. 2017;7:Doc07.
36. Pascuzzi RM. The edrophonium test. *Semin Neurol*. 2003;23(1):83-88.
37. Chiou-Tan FY, Gilchrist JM. Repetitive nerve stimulation and single-fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: Review of recent literature. *Muscle Nerve*. 2015;52(3):455-462.
38. Andrews PI. Autoimmune myasthenia gravis in childhood. *Semin Neurol*. 2004;24(1):101-110.
39. Le TD, Liu ES, Adatia FA, Buncic JR, Blaser S. The effect of adding orbital computed tomography findings to the Chandler criteria for classifying pediatric orbital cellulitis in predicting which patients will require surgical intervention. *J AAPOS*. 2014;18(3):271-277.
40. Harris GJ. Subperiosteal abscess of the orbit. Age as a factor in the bacteriology and response to treatment. *Ophthalmology*. 1994; 101(3):585-595.
41. Chandler JR, Langenbrunner DJ, Stevens ER. The pathogenesis of orbital complications in acute sinusitis. *Laryngoscope*. 1970; 80(9):1414-1428.
42. Ryan JT, Preciado DA, Bauman N, et al. Management of pediatric orbital cellulitis in patients with radiographic findings of subperiosteal abscess. *Otolaryngol Head Neck Surg*. 2009;140(6):907-911.
43. Davies BW, Smith JM, Hink EM, Durairaj VD. C-Reactive Protein As a Marker for Initiating Steroid Treatment in Children With Orbital Cellulitis. *Ophthalm Plast Reconstr Surg*. 2015;31(5):364-368.
44. Shields CL, Shields JA, Honavar SG, Demirci H. Clinical spectrum of primary ophthalmic rhabdomyosarcoma. *Ophthalmology*. 2001; 108(12):2284-2292.
45. Sohaib SA, Moseley I, Wright JE. Orbital rhabdomyosarcoma—the radiological characteristics. *Clin Radiol*. 1998;53(5):357-362.
46. Qualman SJ, Coffin CM, Newton WA, et al. Intergroup Rhabdomyosarcoma Study: update for pathologists. *Pediatr Dev Pathol*. 1998;1(6):550-561.
47. Meza JL, Anderson J, Pappo AS, Meyer WH, Children's Oncology G. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. *J Clin Oncol*. 2006; 24(24):3844-3851.
48. Borinstein SC, Steppan D, Hayashi M, et al. Consensus and controversies regarding the treatment of rhabdomyosarcoma. *Pediatr Blood Cancer*. 2018;65(2).
49. Standridge SM. Idiopathic intracranial hypertension in children: a review and algorithm. *Pediatr Neurol*. 2010;43(6):377-390.
50. Wan MJ, Adebona O, Benson LA, Gorman MP, Heidary G. Visual outcomes in pediatric optic neuritis. *Am J Ophthalmol*. 2014; 158(3):503-507 e502.
51. Verwey P. Measuring vision in children. *Community Eye Health*. 2004;17(50):27-29.
52. Sprague JB, Stock LA, Connett J, Bromberg J. Study of chart designs and optotypes for preschool vision screening—I. Comparability of chart designs. *J Pediatr Ophthalmol Strabismus*. 1989;26(4):189-197.
53. Parks MM. Isolated cyclovertical muscle palsy. *Arch Ophthalmol*. 1958;60(6):1027-1035.
54. Buch H, Vinding T. Acute acquired comitant esotropia of childhood: a classification based on 48 children. *Acta Ophthalmol*. 2015; 93(6):568-574.
55. Hoyt CS, Good WV. Acute onset concomitant esotropia: when is it a sign of serious neurological disease? *Br J Ophthalmol*. 1995;79(5):498-501.
56. Yang WC, Lin MJ, Chen CY, Wu HP. Clinical overview of hypertensive crisis in children. *World J Clin Cases*. 2015;3(6):510-513.
57. Turk A, Ceylan OM, Arici C, et al. Evaluation of the nerve fiber layer and macula in the eyes of healthy children using spectral-domain optical coherence tomography. *Am J Ophthalmol*. 2012;153(3): 552-559 e551.
58. Yanni SE, Wang J, Cheng CS, et al. Normative reference ranges for the retinal nerve fiber layer, macula, and retinal layer thicknesses in children. *Am J Ophthalmol*. 2013;155(2):354-360 e351.

*The authors stated that they have no disclosures to report in association with the contents of this issue.*

Change of address notices and requests for subscriptions for *Ophthalmology Rounds* are to be sent by mail to P.O. Box 310, Station H, Montreal, Quebec H3G 2K8 or by fax to (514) 932-5114 or by e-mail to [info@snellmedical.com](mailto:info@snellmedical.com). Please reference *Ophthalmology Rounds* in your correspondence. Undeliverable copies are to be sent to the address above. Publications Post #40032303

*Ophthalmology Rounds* is made possible through educational support from  
**Novartis Pharmaceuticals Canada Inc.**

© 2018 Department of Ophthalmology and Vision Sciences, Faculty of Medicine, University of Toronto, which is solely responsible for the contents. Publisher: **SNELL Medical Communication Inc.** in cooperation with the Department of Ophthalmology and Vision Sciences, Faculty of Medicine, University of Toronto. \**Ophthalmology Rounds* is a registered trademark of **SNELL Medical Communication Inc.** All rights reserved. The administration of any therapies discussed or referred to in *Ophthalmology Rounds* should always be consistent with the approved prescribing information in Canada. **SNELL Medical Communication Inc.** is committed to the development of superior Continuing Medical Education.